Clinical trials: Plaque Psoriasis.
Psoriatic Subjects
To Evaluate the Efficacy and Safety of RSS0393 Ointment in Patients With Plaque Psoriasis Phase II Study
To evaluate the efficacy and safety of RSS0393 ointment in patients with plaque psoriasis Phase II study
- Trial name
- NCT06918743
- Testing
- RSS0393 ointment
- Volunteers
- 147 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Psoriasis
Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis
This was a multicenter, randomized, vehicle-controlled, double-blind parallel group study to evaluate the efficacy and safety of CD 2027 Oily Spray applied twice daily for 8 weeks in participants with plaque-type psoriasis.
- Trial name
- NCT00763555
- Testing
- CD 2027, Calcitriol Vehicle
- Where
- 6 sites in United States, Canada
- Volunteers
- 88 people
- Sponsor
- Galderma R&D
Rheumatoid Arthritis, Ankylosing Spondylitis
Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice
The purpose of this non-interventional, multicenter, post-marketing observational study (PMOS) was to assess rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), plaque psoriasis (PS), Crohn's…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Crohn´s Disease
- Trial name
- Adherence (NCT01768858)
- Testing
- Adalimumab
- Volunteers
- 96 people
- Sponsor
- AbbVie
Psoriasis
A Study of Mirikizumab in Participants With Plaque Psoriasis
This study is known as a "drug interaction study." The purpose is to learn how commonly used drugs or substances (midazolam, warfarin, dextromethorphan, omeprazole, and caffeine) and their breakdown products get into the…
- Trial name
- NCT03718884
- Testing
- Drug Cocktail, Mirikizumab
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis
Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis
The objective of the study is to evaluate the safety and efficacy of a topical lotion
- Trial name
- NCT02045277
- Testing
- IDP-118 Lotion, IDP-118 Monad HP Lotion, IDP-118 Monad Taz Lotion
- Where
- 18 sites in United States
- Volunteers
- 212 people
- Sponsor
- Bausch Health Americas, Inc.
Psoriasis Vulgaris
Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis
An international, multi-centre, prospective, open-label, non-controlled, single-group, 4-week trial in adolescent subjects with plaque psoriasis.
- Trial name
- NCT02387853
- Testing
- LEO 90100
- Where
- 9 sites in United States, Netherlands and 2 more
- Volunteers
- 117 people
- Sponsor
- LEO Pharma
Psoriasis
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
The purpose of this study is to investigate the long-term safety and efficacy of risankizumab in the treatment of moderate to severe chronic plaque psoriasis.
- Trial name
- LIMMITLESS (NCT03047395)
- Testing
- risankizumab
- Where
- 233 sites in United States, Australia and 15 more
- Volunteers
- 2,170 people
- Sponsor
- AbbVie
Psoriasis
Evaluation of Efficacy, Duration of Remission and Safety of a Light and Occlusive Patch Therapy for Plaque Psoriasis
This is a proof of concept, investigator blinded study to evaluate the efficacy and safety of a novel combination of a home narrow band ultraviolet B (NBUVB) lamp with an occlusive dressing in adult subjects with mild to moderate…
- Trial name
- NCT03180866
- Testing
- Luma Light System
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Illumicure Inc
Moderate-to-severe Plaque Psoriasis
A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis
The primary objective of this study is to evaluate the efficacy and safety of HS-20137 in the treatment of participants with moderate to severe plaque psoriasis.
- Trial name
- NCT06844799
- Testing
- HS-20137
- Volunteers
- 720 people
- Sponsor
- Hansoh BioMedical R&D Company
Psoriasis
A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis
Psoriasis is a chronic disease characterized by marked inflammation and thickening of the skin that results in thick, scaly skin plaques.
- Trial name
- NCT05044234
- Testing
- Cedirogant
- Where
- 53 sites in United States, Canada and 1 more
- Volunteers
- 156 people
- Sponsor
- AbbVie
Plaque Psoriasis
Investigation With BiopH+Psoriasis Medical Bath in Subject With Mild to Moderate Plaque Psoriasis.
The purpose of this investigation is to assess performance and safety of BIOpH+ Psoriasis Medical Bath in comparison to a comparative device.
- Trial name
- NCT05046899
- Testing
- BIOpH+ Psoriasis Medical Bath, Cetaphil Moisturizing Lotion
- Where
- Sweden
- Volunteers
- 25 people
- Sponsor
- Biocool AB
Plaque Psoriasis
Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis
This study was a non-interventional, retrospective study collecting data from hospital medical records. Approximately 200 adult patients with moderate to severe plaque psoriasis who were treated with secukinumab from hospitals in…
- Trial name
- NCT05650060
- Testing
- Secukinumab
- Where
- Thailand
- Volunteers
- 163 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study
The objective of this study is to evaluate the potential of desoximetasone 0.25% topical spray to suppress HPA axis function. The potential for adrenal suppression will be assessed following multiple dosing with Desoximetasone…
- Trial name
- NCT01043393
- Testing
- Desoximetasone 0.25% spray
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Plaque-Type Psoriasis
A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis
The purpose of the study is to determine the efficacy and safety of two different forms of a topical steroid (clobetasol propionate) in patients with plaque-type psoriasis.
- Trial name
- NCT00852761
- Testing
- Olux-E Foam, Clobex lotion
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Stiefel, a GSK Company
Psoriasis
A Registry of Patients With Moderate to Severe Plaque Psoriasis
The main purpose of the current study will be to provide real - world evidence regarding the safety and effectiveness of secukinumab in the management of patients with moderate to severe chronic plaque psoriasis.
- Trial name
- PURE (NCT02786186)
- Testing
- Secikinumab
- Where
- 13 sites in Canada
- Volunteers
- 2,376 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Plaque Psoriasis
Assess the Long-term Effectiveness and Safety of Amevive (Alefacept) in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The study is a prospective, multi-centre, observational study designed to assess the long-term effectiveness and safety of alefacept in subjects with moderate to severe chronic plaque psoriasis.
- Trial name
- AWARE-2 (NCT00795353)
- Testing
- Amevive exposure
- Where
- 21 sites in Canada
- Volunteers
- 64 people
- Sponsor
- Astellas Pharma Inc
Psoriasis
International Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque Psoriasis
BCD-085-2 is a next step in clinical investigation of BCD-085. BCD-085 is a monoclonal antibody to interleukin 17. During BCD-085-2 trial patients with moderate to severe plaque psoriasis, in whom poor response to previous…
- Trial name
- NCT02762994
- Testing
- BCD-085
- Where
- Russia
- Volunteers
- 120 people
- Sponsor
- Biocad
Plaque Psoriasis
Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects
The purpose of this research study is to evaluate the safety and tolerability of ILV-095 when it is given to individuals with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01010542
- Testing
- ILV-095 300 mg in a 4 to 1 ratio
- Where
- 9 sites in United States, Canada
- Volunteers
- 39 people
- Sponsor
- Pfizer
Psoriasis
Study in Patients With Mild to Moderate Psoriasis
This was a randomized, double blind,fixed dose, placebo controlled, parallel-group pilot study to obtain data on size and variance of treatment effects in subjects with mild to moderate Psoriasis.
- Trial name
- AH-PSR-01 (NCT01451346)
- Testing
- B. Infantis 35624
- Where
- Ireland
- Volunteers
- 47 people
- Sponsor
- Alimentary Health Ltd
Moderate Plaque Psoriasis, Moderate Psoriasis
Study to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque Psoriasis in a Real-life Setting in Greece
Psoriasis is a skin disorder wherein skin cells multiply faster than normal, making the skin itchy and look patchy and red. It is caused by an overactive immune system where the body attacks healthy tissue by mistake.
- Conditions
- Moderate Plaque Psoriasis, Moderate Psoriasis, Psoriasis
- Trial name
- REDEFINE (NCT06247319)
- Where
- 22 sites in Greece
- Volunteers
- 250 people
- Sponsor
- AbbVie